To explore a new therapeutic strategy for preventing the occurrence of LPS-induced lung inflammation and injury, we attempted to inhibit JNK or ERK activity by pretreatment with a selective JNK inhibitor, SP600125, or a specific inhibitor of MEK/ERK, PD98059, 1 hour before LPS treatment. This evidence concerns the gene MAP2K7 and inflammation.